SCHEMBL257344

SCHEMBL257344

Cc1nc(C(=O)c2ccccc2)sc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.57
KDM4E B2RXH2 5/20 0.54
KMT2A Q03164 2/20 0.54
RAB9A P51151 6/20 0.52
NPC1 O15118 6/20 0.52
ALDH1A1 P00352 4/20 0.52
MAPT P10636 3/20 0.52
POLB P06746 2/20 0.52
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
CHRM4 P08173 3/20 0.46
MEN1 O00255 1/20 0.44
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15197079 0.89 ALDH1A1 (0.52) SMN1; SMN2KDM4EKMT2ARAB9ANPC1
SCHEMBL257340 0.82 NPC1 (0.59) SMN1; SMN2KDM4EKMT2ARAB9ANPC1
SCHEMBL8867115 0.78 SMN1; SMN2 (0.77) SMN1; SMN2KDM4EKMT2ARAB9ANPC1
SCHEMBL3655946 0.78 ALDH1A1 (0.61) SMN1; SMN2KDM4EKMT2ARAB9ANPC1
SCHEMBL1667192 0.76 CCNA2 (0.45) SMN1; SMN2KDM4EKMT2ARAB9ANPC1
SCHEMBL27972473 0.76 RAB9A (0.63) SMN1; SMN2KDM4EKMT2ARAB9ANPC1
SCHEMBL8866740 0.75 SMN1; SMN2 (0.71) SMN1; SMN2KDM4EKMT2ARAB9ANPC1
SCHEMBL28478357 0.74 CCNA2 (0.55) KDM4EKMT2ARAB9ANPC1ALDH1A1
SCHEMBL3582729 0.73 NPC1 (0.73) SMN1; SMN2KDM4EKMT2ARAB9ANPC1
SCHEMBL31675965 0.73 ALDH1A1 (0.55) SMN1; SMN2KDM4EKMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 SMN1; SMN2 2704/4885KDM4E 2413/4885KMT2A 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.